Elan reports "solid" start to 2012
UPDATE: Elan has reported a 17 per cent rise in revenues for the first quarter of the year and says opportunities in neurology are significant.
Elan has reported a 17 per cent rise in revenues for the first quarter of the year.
Revenues at the firm that focuses on neurological disorders totalled $288.4 million in the three months, Elan said.
Revenue from its multiple sclerosis drug Tysabri totalled $288.2 million, which was just ahead of expectations according to Bloomberg News.
Subscribe from just €1 for the first month!
What's Included
With any subscription you will have access to
-
Unlimited multi-device access to our iPad, iPhone and Android Apps
-
Unlimited access to our eReader library
-
Exclusive daily insight and opinion seven days a week
-
Create alerts to never miss a subject that matters to you
-
Get access to exclusive offers for subscribers on gifts and experiences
-
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Related Stories
The year in review
The best writing and and the biggest stories of 2019 from the Business Post
Newsround: What Thursday’s papers say
Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals
More cycle routes, expansion of Luas to Bray and new bus network proposed
Greater Dublin Area draft Transport Strategy published
